Boehringer Ingelheim’s investigational biologic cleared skin better, faster and for longer than ustekinumab in phase II psoriasis study
8.10.2015 11:17 | Business Wire
New results from a Phase II head-to-head psoriasis study showed superior efficacy of Boehringer Ingelheim’s investigational biologic compound BI 655066*, over ustekinumab. After nine months, 69 percent of patients with moderate-to-severe plaque psoriasis maintained clear or almost clear skin (PASI 90) with BI 655066 in the higher dose group compared to 30 percent of patients on ustekinumab.1 Patients also achieved this skin clearance significantly faster (approximately eight weeks versus approximately 16 weeks) and for more than two months longer (≥ 32 weeks versus 24 weeks) than those on ustekinumab. In addition, completely clear skin (PASI 100) was maintained after nine months in nearly triple the percentage of patients on BI 655066* compared with ustekinumab (43 percent versus 15 percent).1
"These results are striking. They further strengthen our understanding of the potential skin improvement that can be achieved with BI 655066, in moderate-to-severe plaque psoriasis. We saw a third more patients achieve clearer skin in a short time period. And this clearance was maintained longer compared to the commonly used treatment ustekinumab,” commented Kim A. Papp, MD, PhD, President of Probity Medical Research, Waterloo, Ontario, Canada. “Achieving clear skin quickly and maintaining clearance is an important goal for patients that have to deal with the daily impact of psoriasis.”
These meaningful 24-week findings from a Phase II study in psoriasis were presented today in an oral presentation by Dr Kim A. Papp at the 24th European Academy of Dermatology and Venereology (EADV) congress in Copenhagen.
The study (NCT02054481) investigated the efficacy and safety of BI 655066 versus ustekinumab in 166 patients.1 These data build on Phase II data presented earlier this year at the Annual Meeting of the American Academy of Dermatology (AAD). Primary endpoint results showed nearly double the percentage of patients with moderate-to-severe plaque psoriasis achieved clear or almost clear skin (PASI 90) after 12 weeks of treatment with BI 655066, compared to ustekinumab (77.1 percent versus 40 percent of patients). The new data further demonstrate that BI 655066 has similar safety and tolerability to ustekinumab, regardless of dose, with no serious drug-related side-effects.1 The most common side effects were runny nose, sore throat, and headache.1
“The results are an exciting milestone in Boehringer Ingelheim’s growing immunology pipeline. These Phase II study results represent a major step towards our vision of transforming the treatment of immune diseases and the patients affected by it,” said Dr. Steven Padula, Therapeutic Area Head Medicine Immunology at Boehringer Ingelheim. “We look forward to continued research and are currently planning multiple Phase III studies.”
Additional trial information
The data discussed in this press release represent results for BI 655066 180mg (n=42) injection under the skin, delivered at weeks zero, four and 16.
The BI 655066 90mg (n=41) dose also showed superior efficacy, onset and duration of action over ustekinumab after nine months.1
- More patients with moderate-to-severe psoriasis maintained almost clear skin (PASI 90) with BI 655066 compared to those on ustekinumab (81 percent versus 30 percent)1
- More patients on BI 655066 had completely clear skin (PASI 100) compared with ustekinumab (54 percent versus 15 percent)1
An exploratory single dose of BI 655066 18mg (n=43) was also studied.1
Ustekinumab 45mg/90mg (n=40) was delivered as an injection under the skin at weeks zero, four and 16.
Registered media can view the abstract online.
*BI 655066 is not approved by regulatory authorities and its safety and efficacy is being investigated.
For additional information, click here to view the Facts about Psoriasis fact sheet.
If you are attending the EADV congress, visit us at the Boehringer Ingelheim booth, number 147.
For notes to editors and references please visit:
Media + PR
Phone: +49 (6132) 77 8271
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Out-of-this-World Science Project to be Featured as Keynote at SC17’s High Performance Computing Conference in Denver16.8.2017 13:00 | Pressemelding
Professor Philip Diamond, Director General of the international Square Kilometer Array (SKA) project, will be the keynote speaker at SC17, the International Conference for High Performance Computing, Networking, Storage and Analysis in Denver, Nov. 12-17. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170816005129/en/ SC17 Keynote Speaker Philip Diamond (Photo: Business Wire) SKA is an international collaboration to build the world’s largest radio telescope that will change our understanding of space as we know it. Professor Diamond, accompanied by Dr. Rosie Bolton, SKA Regional Centre Project Scientist, will take SC17 attendees around the globe and out into the deepest reaches of the observable universe as they describe the SKA’s international partnership that will map and study the e
Scientist.com Ranks No. 155 on the 2017 Inc. 5000 List of Fastest-Growing Companies16.8.2017 12:06 | Pressemelding
Scientist.com, the leading marketplace for outsourced scientific services, today announced that it ranked no. 155 on Inc. magazine’s 2017 List of the 5000 Fastest-Growing privately-owned companies in America, and it ranked no. 11 in the country in the Health category. The San Diego-based company builds private marketplaces that connect many of the world’s largest life science research organizations with a global network of thousands of research suppliers. “Using Scientist.com, research organizations of pharmaceutical companies, biotech start-ups and academic and research institutes can get near instant access to thousands of the latest research technologies and services,” stated Paul A. Stone, JD, Partner at 5AM Ventures, a Scientist.com investor. “The marketplace saves researchers time, reduces costs, promotes access to innovation and ensures regulatory compliance. Scientist.com is im
CMB Successfully Goes-Live on Murex’s MX.3 Platform16.8.2017 08:00 | Pressemelding
Murex, a global leader in trading, risk management and processing solutions, is pleased to announce the successful launch of the MX.3 platform at China Merchants Bank (CMB). As one of China’s largest commercial banks, CMB financial market department currently averages 8,000 trades per day with a portfolio of 320,000 live trades on MX.3. CMB decided to launch the project to implement an enterprise-wide solution for their capital markets teams based in Shenzhen and Shanghai. This was done in order to improve control over their end-to-end trading cycle from front-to-back through risk, streamline and automate their operations, and enable new business. Murex’s MX.3 platform was selected as it provided the functional, geographical and product coverage that was required by the bank. Covering Front Office, Processing, Finance, and Risk Management, MX.3 also provides VaR analytics across all asset
euNetworks Adds New High Density Fibre Network in Manchester16.8.2017 08:00 | Pressemelding
euNetworks, a provider of bandwidth services in Europe, today announced it has made further investment in Manchester in the United Kingdom, having built out a new high density fibre network covering over 40 route kilometres in the city. This follows initial expansion into Manchester’s MediaCityUK in May 2016, which supported euNetworks’ Media customer’s bandwidth needs, as well as enabling a seamless network experience from London through to Manchester and Dublin and onwards to Europe. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170816005067/en/ euNetworks Fibre in Manchester (Photo: Business Wire) This new network in Manchester city was designed for resilience, with fully diverse nodes. euNetworks undertook a combination of new construction and duct acquisition to complete this network
The Peninsula Classics Best of the Best Award for 2016 Awarded to 1954 Maserati A6GCS/53 Berlinetta by Pinin Farina16.8.2017 07:28 | Pressemelding
At a highly-anticipated private gathering during the famed Monterey Car Week, a 1954 Maserati A6GCS/53 Berlinetta by Pinin Farina, from the Monaco-based Destriero Collection, was named winner of the prestigious second-annual The Peninsula Classics Best of the Best Award . This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170816005384/en/ 1954 Maserati A6GCS/53 Berlinetta by Pinin Farina was named winner of the prestigious The Peninsula Classics Best of the Best Award. Photo Credit: Adam Swords Only four Berlinetta-bodied sports cars from Pinin Farina were ever produced, and this exquisite model is considered to be the best preserved, as it is the only one that retains its original chassis and body. Custom ordered by the Roman dealer of the marque, the sports car is
Lion/Gem Luxembourg 3 S.a.r.l. Announces Third Quarter Results for FY 201716.8.2017 06:00 | Pressemelding
The Third Quarter results for FY17 for Lion/Gem Luxembourg 3 S.a.r.l. (associated with Young’s Seafood Limited) will be made available on our Investor Relations website on August 16, 2017. The Third Quarter FY17 Call for investors that accompanies this information is scheduled to take place at 13:00 BST (GMT +0100) on August 16, 2017. The Third Quarter covers the quarter to July 1 2017; the financial year end for Lion/Gem Luxembourg 3 S.a.r.l. is September 30 2017. For further information: If you are an investor or a potential investor in the 8¼%/ 9% Senior PIK Notes due 2019, of Lion/Gem Luxembourg 3 S.a.r.l., and would like access to this information, please register your interest on our Investor Relations website: https://youngsseafood.co.uk/investors/ If you have any questions about the registration process or need further information, please do not hesitate
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom